Delayed
Nasdaq
09:42:39 24/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.402
USD
|
+7.86%
|
|
+0.16%
|
-11.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
41.22
|
19.03
|
31.35
|
12.04
|
45.46
|
37.33
|
-
|
-
|
Enterprise Value (EV)
1 |
41.22
|
19.03
|
31.35
|
12.04
|
45.46
|
37.33
|
37.33
|
37.33
|
P/E ratio
|
-4.86
x
|
-0.78
x
|
-1.67
x
|
-0.78
x
|
-1.29
x
|
-1.76
x
|
-2.17
x
|
-4.64
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
40.9
x
|
21.1
x
|
19.8
x
|
8.75
x
|
42.2
x
|
22
x
|
17.7
x
|
2.3
x
|
EV / Revenue
|
40.9
x
|
21.1
x
|
19.8
x
|
8.75
x
|
42.2
x
|
22
x
|
17.7
x
|
2.3
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-2.21
x
|
-
|
-
|
-
|
-1.72
x
|
-1.54
x
|
-
|
FCF Yield
|
-
|
-45.2%
|
-
|
-
|
-
|
-58.1%
|
-64.8%
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-2.6
x
|
-1
x
|
-
|
Nbr of stocks (in thousands)
|
1,212
|
4,375
|
8,405
|
8,482
|
28,591
|
28,716
|
-
|
-
|
Reference price
2 |
34.00
|
4.350
|
3.730
|
1.420
|
1.590
|
1.300
|
1.300
|
1.300
|
Announcement Date
|
30/03/20
|
12/03/21
|
11/03/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1.007
|
0.9034
|
1.586
|
1.376
|
1.076
|
1.698
|
2.107
|
16.26
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.545
|
-8.961
|
-14.29
|
-15.62
|
-20.05
|
-21.52
|
-23.3
|
-15.29
|
Operating Margin
|
-749.06%
|
-991.99%
|
-901.15%
|
-1,135.51%
|
-1,862.68%
|
-1,267.22%
|
-1,105.81%
|
-94%
|
Earnings before Tax (EBT)
1 |
-7.533
|
-8.942
|
-14.29
|
-15.45
|
-20.06
|
-21.45
|
-23.24
|
-15.29
|
Net income
1 |
-7.533
|
-8.942
|
-14.29
|
-15.45
|
-20.06
|
-21.45
|
-23.24
|
-15.29
|
Net margin
|
-747.87%
|
-989.79%
|
-900.93%
|
-1,123.08%
|
-1,863.35%
|
-1,263.29%
|
-1,102.64%
|
-94%
|
EPS
2 |
-7.000
|
-5.600
|
-2.240
|
-1.830
|
-1.230
|
-0.7400
|
-0.6000
|
-0.2800
|
Free Cash Flow
1 |
-
|
-8.593
|
-
|
-
|
-
|
-21.7
|
-24.2
|
-
|
FCF margin
|
-
|
-951.24%
|
-
|
-
|
-
|
-1,277.97%
|
-1,148.37%
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
12/03/21
|
11/03/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.5851
|
0.1949
|
0.5419
|
0.4522
|
0.1868
|
0.1524
|
0.1171
|
0.4955
|
0.3114
|
0.2024
|
0.476
|
0.4983
|
0.4387
|
0.3
|
0.25
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.793
|
-2.934
|
-3.456
|
-4.248
|
-4.983
|
-5.007
|
-4.633
|
-4.767
|
-5.643
|
-5.121
|
-5
|
-5.1
|
-6.1
|
-5.5
|
-5.4
|
Operating Margin
|
-477.39%
|
-1,505.62%
|
-637.77%
|
-939.58%
|
-2,667.51%
|
-3,285.3%
|
-3,955.72%
|
-962.19%
|
-1,811.98%
|
-2,529.54%
|
-1,050.42%
|
-1,023.42%
|
-1,390.57%
|
-1,833.33%
|
-2,160%
|
Earnings before Tax (EBT)
1 |
-2.792
|
-2.772
|
-3.452
|
-4.247
|
-4.98
|
-5.007
|
-4.636
|
-4.771
|
-5.642
|
-4.343
|
-5
|
-5.1
|
-6.1
|
-5.3
|
-5.4
|
Net income
1 |
-2.792
|
-2.772
|
-3.452
|
-4.247
|
-4.98
|
-5.007
|
-4.636
|
-4.771
|
-5.642
|
-4.343
|
-5
|
-5.1
|
-6.1
|
-5.3
|
-5.4
|
Net margin
|
-477.23%
|
-1,422.06%
|
-637.03%
|
-939.22%
|
-2,666.18%
|
-3,285.28%
|
-3,958.73%
|
-962.98%
|
-1,811.95%
|
-2,145.25%
|
-1,050.42%
|
-1,023.42%
|
-1,390.57%
|
-1,766.67%
|
-2,160%
|
EPS
2 |
-0.3400
|
-0.3300
|
-0.4100
|
-0.5000
|
-0.5900
|
-0.4600
|
-0.3300
|
-0.2900
|
-0.2300
|
-0.1500
|
-0.1700
|
-0.1533
|
-0.1567
|
-0.1600
|
-0.1550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/03/22
|
12/05/22
|
15/08/22
|
10/11/22
|
17/03/23
|
12/05/23
|
14/08/23
|
14/11/23
|
18/03/24
|
15/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-8.59
|
-
|
-
|
-
|
-21.7
|
-24.2
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
-
|
-0.5000
|
-1.300
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/03/20
|
12/03/21
|
11/03/22
|
17/03/23
|
18/03/24
|
-
|
-
|
-
|
Average target price
3.2
USD Spread / Average Target +146.15% Consensus |
1st Jan change
|
Capi.
|
---|
| -11.81% | 37.33M | | +38.78% | 728B | | +33.05% | 603B | | -5.49% | 360B | | +18.98% | 332B | | +1.47% | 279B | | +16.00% | 244B | | +8.09% | 207B | | -5.77% | 205B | | +6.51% | 164B |
Other Pharmaceuticals
|